# A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

> **NCT00531752** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 66 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** PF-03654746
- **DRUG:** Placebo capsules
- **DRUG:** PF-03654746

## Key facts

- **NCT ID:** NCT00531752
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2016-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531752

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531752, "A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT00531752. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*